NICE, the health technology assessment (HTA) body for England, has recommended interim funding for Daiichi Sankyo/AstraZeneca’s Enhertu (trastuzumab deruxtecan), claiming the move makes England the first country in Europe to commission the advanced breast cancer drug.
NICE Funding Wins For Enhertu & Kesimpta Are Firsts For England
More Data Needed Before Enhertu Can Be Made Routinely Available on NHS
UK health technology assessment body NICE has struck deals with the makers of Enhertu for advanced breast cancer and Kesimpta for relapsing forms of multiple sclerosis.
